183859-36-1

Basic information

• Product Name: Piperidin-2-yl-acetic acid methyl ester, hydrochloride
• Synonyms: Piperidin-2-yl-acetic acid methyl ester, hydrochloride;tert-Butyl 2-(2-methoxy-2-oxoethyl);VJNWVGAZYYQKTF-UHFFFAOYSA-N
• CAS NO: 183859-36-1
• Molecular Formula: C8H16ClNO2
• Molecular Weight: 193.67114
• Mol File: 183859-36-1.mol

Chemical Properties

• Boiling Point: 213.1°C at 760 mmHg
• Flash Point: 82.7°C
• Appearance: /
• Density: 0.982g/cm³
• Vapor Pressure: 0.167mmHg at 25°C
• Refractive Index: 1.439
• CAS DataBase Reference: Piperidin-2-yl-acetic acid methyl ester, hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Piperidin-2-yl-acetic acid methyl ester, hydrochloride(183859-36-1)
• EPA Substance Registry System: Piperidin-2-yl-acetic acid methyl ester, hydrochloride(183859-36-1)

Safety Data

• Hazardous Substances Data: 183859-36-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
Piperidin-2-yl-acetic acid methyl ester, hydrochloride is used as a key intermediate in the synthesis of various pharmaceuticals, particularly those targeting the central nervous system. Its unique chemical structure and properties make it a valuable asset in the development of new drugs with potential therapeutic applications.
Used in Drug Synthesis:
Piperidin-2-yl-acetic acid methyl ester, hydrochloride is used as a precursor in the synthesis of other important chemical compounds, contributing to the advancement of pharmaceutical chemistry and the discovery of novel therapeutic agents.
Used in Drug Development:
Piperidin-2-yl-acetic acid methyl ester, hydrochloride is utilized in the development of new pharmaceutical drugs, where its unique properties and reactivity can be harnessed to create innovative and effective treatments for various medical conditions.
Used in Laboratory Settings:
The hydrochloride salt form of Piperidin-2-yl-acetic acid methyl ester, hydrochloride makes it more stable and easier to handle in laboratory settings, facilitating its use in research and development processes.
Overall, Piperidin-2-yl-acetic acid methyl ester, hydrochloride is a versatile and essential chemical compound in the pharmaceutical industry, with a wide range of applications in drug synthesis, research, and development.

InChI:InChI=1/C8H15NO2/c1-11-8(10)6-7-4-2-3-5-9-7/h7,9H,2-6H2,1H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 24153-01-3 piperidin-2-yl-acetic acid methyl ester hydrochloride 
• 13115-43-0 2-pyridineacetic acid 
• 1484-84-0 2(RS)-(2-hydroxyethyl)piperidine 
• 98303-20-9 1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid 
• 7440-44-0 pyrographite 
• 118811-03-3 tert-butyl 2-(2-hydroxyethyl)piperidine-1-carboxylate 
• 19615-30-6 piperidin-2-yl-acetic acid hydrochloride 
• 67-56-1 methanol 
• 19832-04-3 2-(piperidin-2-yl)acetic acid 
• 132910-79-3 (+/-) methyl N-tert-butyloxycarbonyl 2-piperidinecarboxylate 
• 74-95-3 1,1-dibromomethane 
• 186581-53-3 diazomethane 
• 149518-50-3 2-(1-(tert-butoxycarbonyl)-2-piperidinyl)acetic acid 

Downstream Products

• 159898-10-9 (S)-2-{1-[(tert-butoxy)carbonyl]piperidin-2-yl}acetic acid 
• 813433-73-7 (R)-2-methoxycarbonylmethylpiperidine-1-carboxylic acid tert-butyl ester 
• 118811-03-3 tert-butyl 2-(2-hydroxyethyl)piperidine-1-carboxylate 
• 486-89-5 (+/-)-thermopsine 
• 131134-77-5 (S)-2-(methoxycarbonylmethyl)piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Chemoenzymatic approach to enantiopure piperidine-based β-amino esters in organic solvents

This research concentrates on the enantioselectivities of lipase-catalysed reactions with methyl esters of 2-piperidylacetic acid and 3-piperidinecarboxylic acid derivatives. N-Acetylated 2-piperidylacetic acid methyl ester displayed good enantioselectivi

Enzymatic resolution of cyclic N-Boc protected β-aminoacids

Methyl and ethyl esters of N-Boc homoproline, homopipecolic acid and 3-carboxymethyl-morpholine were kinetically resolved by hydrolysis catalysed by Burkholderia cepacia lipase to give the corresponding acids and residual esters in enantiomeric excesses better than 99% (E > 100).

Kowalski ester homologation. Application to the synthesis of β-amino esters

The Kowalski ester homologation protocol has been applied to a representative range of α-amino esters to provide β-amino esters with excellent levels of enantio- and diastereocontrol. A key feature of this chemistry is the nature of the N-protecting group that is employed.

Complex-induced proximity effects: The effect of varying directing-group orientation on carbamate-directed lithiation reactions

A series of selected bicyclic carbamates in which the range of accessible angles and distances between the carbonyl group and the proton removed in an α-lithiation reaction are structurally defined have been investigated. Oxazolidinones 7-10 undergo stereoselective lithiation-substitution reactions to provide cis-18-27 and cis-31-35 as the major diastereomers. Two series of competition experiments show that the conformationally restricted carbamates 7, 10, 11, and 15 undergo lithiation via complexes more efficiently than Boc amines 4-6. These results along with semiempirical calculations suggest that a small dihedral angle and a calculated distance of 2.78 A between the carbamate carbonyl oxygen and the proton to be removed are favorable for a carbamate-directed lithiation. A series of tin-lithium exchange experiments on cis- and trans-18 and (S)-39 indicate that the configurational stability of a carbamate-stabilized organolithium species may be enhanced by restrictive geometry.

Antagonists of gonadotropin releasing hormone

PCT No. PCT/US97/08428 Sec. 371 Date Nov. 12, 1998 Sec. 102(e) Date Nov. 12, 1998 PCT Filed May 16, 1997 PCT Pub. No. WO97/44037 PCT Pub. Date Nov. 27, 1997There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related conditions in both men and women.

Antagonists of gonadotropin releasing hormone

PCT No. PCT/US97/08782 Sec. 371 Date Nov. 12, 1998 Sec. 102(e) Date Nov. 12, 1998 PCT Filed May 16, 1997 PCT Pub. No. WO97/44041 PCT Pub. Date Nov. 27, 1997There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related conditions in both men and women.